Abstract
Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth, differentiation, survival and death. Due to their regulatory potential, these nuclear receptors (NRs) are major drug targets for a variety of pathologies, including cancer and metabolic diseases. A large amount of RAR- and RXR-selective ligands, ranging from (partial) agonists to antagonists and inverse agonists, have been designed and the corresponding structural and functional analyses have provided deep insight into the molecular basis of ligand action. Ligands regulate, via allosteric conformational changes, the ability of these NRs to interact with different sets of coregulators, which in turn recruit enzymatically active complexes/machineries. Here, we describe strategies in the design of selective RXR and RAR modulators and review the structural mechanisms by which the diverse pharmacological classes of compounds modulate receptor functions. Finally, we discuss the perspectives for retinoid- and rexinoid-based therapies.
Keywords: Retinoic acid receptors, retinoid X receptors, agonists and antagonists action, ligand design, selective ligands, structure-function relationship, thee-dimensional structure, therapeutic potential, antagonists rexinoid apoptosis, retinoid- and rexinoid-based therapies
Current Topics in Medicinal Chemistry
Title: Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
Volume: 12 Issue: 6
Author(s): Albane le Maire, Susana Alvarez, Pattabhiraman Shankaranarayanan, Angel R de Lera, William Bourguet and Hinrich Gronemeyer
Affiliation:
Keywords: Retinoic acid receptors, retinoid X receptors, agonists and antagonists action, ligand design, selective ligands, structure-function relationship, thee-dimensional structure, therapeutic potential, antagonists rexinoid apoptosis, retinoid- and rexinoid-based therapies
Abstract: Retinoic acid receptors (RARs) are ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth, differentiation, survival and death. Due to their regulatory potential, these nuclear receptors (NRs) are major drug targets for a variety of pathologies, including cancer and metabolic diseases. A large amount of RAR- and RXR-selective ligands, ranging from (partial) agonists to antagonists and inverse agonists, have been designed and the corresponding structural and functional analyses have provided deep insight into the molecular basis of ligand action. Ligands regulate, via allosteric conformational changes, the ability of these NRs to interact with different sets of coregulators, which in turn recruit enzymatically active complexes/machineries. Here, we describe strategies in the design of selective RXR and RAR modulators and review the structural mechanisms by which the diverse pharmacological classes of compounds modulate receptor functions. Finally, we discuss the perspectives for retinoid- and rexinoid-based therapies.
Export Options
About this article
Cite this article as:
le Maire Albane, Alvarez Susana, Shankaranarayanan Pattabhiraman, R de Lera Angel, Bourguet William and Gronemeyer Hinrich, Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators, Current Topics in Medicinal Chemistry 2012; 12 (6) . https://dx.doi.org/10.2174/156802612799436687
DOI https://dx.doi.org/10.2174/156802612799436687 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau
Current Neurovascular Research Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Botulinum Toxin a in Prostate Disease: A Venom from Bench to Bed-Side
Current Drug Delivery 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry A Machine Learning-based Self-risk Assessment Technique for Cervical Cancer
Current Bioinformatics Polymeric Carrier Systems for siRNA Delivery
Current Topics in Medicinal Chemistry Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research Chemoprevention of Breast Cancer by Dietary Compounds
Anti-Cancer Agents in Medicinal Chemistry CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine Role of Adiponectin in Cervical Cancer
Current Drug Metabolism Quality Assessment of Diagnostic Methods Employed for Suspected Lung Cancer
Current Respiratory Medicine Reviews Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Fundamentals of Nanocarriers and Probiotics in the Treatment of Cervical Cancer
Current Nanomedicine Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis